BioCentury | Aug 14, 2020
Deals

EU closing in on COVID-19 vaccine deals with J&J, GSK-Sanofi as COVAX works toward equitable access

The European Commission is close to securing access to two COVID-19 vaccines for its member states. On Thursday, the EU reached a preliminary agreement with J&J for 200 million doses of its adenovirus vector vaccine, after...
BioCentury | Aug 8, 2020
Product Development

Novavax secures multicountry access to COVID-19 vaccine

Building on its commitment to make its COVID-19 vaccine globally accessible, Novavax closed two partnerships this week to supply Japan, India and lower income countries with doses of NVX-CoV2373. The biotech plans to start a...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...
BioCentury | Aug 8, 2020
Deals

Data Bytes: taking stock of Biogen’s pipeline as aducanumab timeline comes into focus

As its high-profile Alzheimer’s candidate aducanumab has inched toward the finish line, Biogen has been diversifying its neurology portfolio beyond the high-risk indication. The biotech has built a pipeline of 26 clinical assets spanning 15...
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

Heading into the second half of the year with cautious optimism, drug developers see opportunities for dealmaking created by COVID-19, as well as challenges. If their predictions are right, infectious deals could surpass cancer transactions....
BioCentury | Aug 7, 2020
Politics, Policy & Law

Gilead disputes need for march-in rights to remdesivir to increase access, lower price

COVID-19 has spurred the latest demand for the federal government to exercise a power, yet unused, to lower drug prices by terminating a manufacturer’s exclusive license. In a letter Tuesday, 34 U.S. attorneys general urged...
BioCentury | Jul 31, 2020
Product Development

Warp Speed’s $2.1B commitment to Sanofi-GSK COVID-19 program brings total to $8.3B across seven vaccines

A preclinical vaccine from Sanofi and GSK may be months behind other COVID-19 vaccines in development, but the U.S. government has made its largest financial commitment yet to its development and manufacturing, pledging up to...
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fourth for COVID-19

This story was updated to correct the nature of Imperial College's deal with the U.K. As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi...
BioCentury | Jul 29, 2020
Emerging Company Profile

Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant

Bright Peak thinks its medicinal chemistry approach to protein design will make its synthetic cytokines stand out from the pack. Built by Versant Ventures’ Basel-based Ridgeline outpost with technology licensed from ETH Zurich, Bright Peak...
BioCentury | Jul 24, 2020
Politics, Policy & Law

FDA lays out right to try reporting requirements

Companies that provide an unapproved therapy to patients via the Right-to-Try Act would be required to report such instances to FDA, according to a rule proposed by the agency Thursday. Under the rule, manufacturers would...
Items per page:
1 - 10 of 12523